SG Americas Securities LLC Boosts Stake in Arrowhead Pharmaceuticals, Inc. $ARWR

SG Americas Securities LLC grew its position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 418.1% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 45,066 shares of the biotechnology company’s stock after buying an additional 36,368 shares during the quarter. SG Americas Securities LLC’s holdings in Arrowhead Pharmaceuticals were worth $1,554,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently modified their holdings of the company. Louisiana State Employees Retirement System lifted its holdings in Arrowhead Pharmaceuticals by 8.3% during the third quarter. Louisiana State Employees Retirement System now owns 63,600 shares of the biotechnology company’s stock worth $2,194,000 after acquiring an additional 4,900 shares during the period. Salomon & Ludwin LLC purchased a new stake in shares of Arrowhead Pharmaceuticals during the 3rd quarter valued at $34,000. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new stake in shares of Arrowhead Pharmaceuticals during the 3rd quarter worth $517,000. HBK Sorce Advisory LLC bought a new stake in shares of Arrowhead Pharmaceuticals during the 3rd quarter worth $2,823,000. Finally, CWM LLC boosted its holdings in shares of Arrowhead Pharmaceuticals by 6.7% in the 3rd quarter. CWM LLC now owns 12,179 shares of the biotechnology company’s stock worth $420,000 after buying an additional 764 shares during the last quarter. 62.61% of the stock is owned by institutional investors.

Analysts Set New Price Targets

ARWR has been the subject of a number of research analyst reports. HC Wainwright raised their price objective on shares of Arrowhead Pharmaceuticals from $80.00 to $85.00 and gave the stock a “buy” rating in a report on Tuesday, December 2nd. Piper Sandler restated an “overweight” rating and set a $110.00 price target (up previously from $100.00) on shares of Arrowhead Pharmaceuticals in a research note on Tuesday. Chardan Capital lifted their price target on shares of Arrowhead Pharmaceuticals from $60.00 to $80.00 and gave the stock a “buy” rating in a report on Wednesday, January 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of Arrowhead Pharmaceuticals in a report on Wednesday, October 8th. Finally, The Goldman Sachs Group raised their target price on Arrowhead Pharmaceuticals from $50.00 to $85.00 and gave the stock a “neutral” rating in a research report on Wednesday, January 7th. Two analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $73.00.

Insider Buying and Selling

In related news, Director Michael S. Perry sold 16,250 shares of the stock in a transaction dated Friday, December 5th. The stock was sold at an average price of $61.03, for a total transaction of $991,737.50. Following the sale, the director owned 115,240 shares of the company’s stock, valued at approximately $7,033,097.20. This represents a 12.36% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Christopher Richard Anzalone sold 130,000 shares of Arrowhead Pharmaceuticals stock in a transaction dated Monday, December 15th. The shares were sold at an average price of $68.85, for a total value of $8,950,500.00. Following the transaction, the chief executive officer directly owned 3,971,255 shares of the company’s stock, valued at $273,420,906.75. The trade was a 3.17% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 510,836 shares of company stock valued at $33,603,060 over the last three months. Insiders own 4.30% of the company’s stock.

Arrowhead Pharmaceuticals Stock Up 0.5%

ARWR opened at $66.25 on Friday. Arrowhead Pharmaceuticals, Inc. has a 12 month low of $9.57 and a 12 month high of $76.76. The company has a market cap of $9.00 billion, a PE ratio of -828.02 and a beta of 1.21. The company has a current ratio of 4.86, a quick ratio of 4.86 and a debt-to-equity ratio of 0.43. The company has a 50 day moving average of $59.36 and a 200 day moving average of $37.88.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.